Business Wire

NTHU

28.10.2021 11:02:08 CEST | Business Wire | Press release

Share
NTHU and DAICEL of Japan to Jointly Develop Revolutionary Desktop Chemical Plant

National Tsing Hua University (NTHU) and the well-known Japanese chemical company DAICEL announce a five-year joint project to integrate an innovative microfluidic system developed by scholar Kitamori Takehiko into the chemical manufacturing industry today. Total investment in the project is 450 million Japanese yen (approximately NT$110 million), and its potential to reduce energy consumption while lowering the production of carbon and waste is expected to set a new standard for sustainability in the chemical industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211028005388/en/

Prof. Kitamori, a world-renowned pioneer in microfluidic and nanofluidic technology and the former vice president of the University of Tokyo, has been serving as the Yushan Honorary Chair Professor of the Institute of Nanoengineering and Microsystems, Department of Power Mechanical Engineering at NTHU since 2020. Building on his previous research conducted at the University of Tokyo, he has developed an innovative microfluidic system which allows the mixing and extracting operations conventionally carried out with large-scale equipment to be performed using a glass chip the size of a business card and capable of combining thousands of microfluidic chips simultaneously, making it possible to create a “desktop chemical plant.”

Kitamori explained that it can be quite difficult to instantaneously mix several large barrels of chemicals with different temperatures and reaction speeds, and there may even be an explosion if the materials are not handled carefully. Thus the preferred way of blending chemicals is by passing it through a microchannel, which makes it possible to precisely control the amount of raw materials used, as well as the mixing sequence and conditions, thereby optimizing the quality of the final product.

Kitamori said that the aim of the project is to reduce the size of chemical production equipment, so that what is currently produced by a factory measuring 20 x 20 meters can be miniaturized into a system only two square meters in size. What’s more, such a system would use less energy and materials, making it less expensive, and would also produce less carbon.

Years ago, when DAICEL president Ogawa Yoshimi heard about the microfluidic technology developed by Kitamori, he was deeply impressed, and is now highly pleased that DAICEL is going to integrate this innovative technology into its operations. He is also looking forward to cooperating with NTHU in introducing this epoch-making manufacturing process to the world, which he also sees as a way of promoting sustainability and the circular economy.

Dr. Fan-gang Tseng, Vice President and Director of Research and Development, NTHU, said that he is very optimistic about the future development of the microfluidic chemical plant. He pointed out that the adoption of this microfluidic process by DAICEL—one of the largest chemical companies in Japan—and by Taiwan’s many small and medium-sized chemical factories would constitute a revolutionary leap forward, and could lead to similar processes being applied by the semiconductor and biomedical industry.

Social Media:

https://www.facebook.com/nthu.tw

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Debiopharm’s Pre-Clinical Proof-Of-Concept Research Unveils the Potential of Novel MultiLINK Linker Technology to Overcome Tumor Resistance14.10.2026 14:00:00 CEST | Press release

Despite the remarkable progress made by ADCs, many cancer patients continue to face disease progression due to treatment resistance, tumor heterogeneity, and dose-limiting toxicities At World ADC 2026 San Diego, Debiopharm presented their latest ADC innovation to overcome these challenges with novel linker-payload technology, including modular dual payload linker MLINK DUO and modular cathepsin B-cleavable linker MLINK Select Research results with various MultiLINKTM Linker Technologies showcased broadening of vedotin-based ADC therapeutic index for MLINK Select ADCs, synergistic antitumor activity with MLINK Duo, and homogeneous DAR8 conjugation with MLINK HiSol Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standards of care to cure cancer and infectious diseases, today announced their latest research on antibody drug conjugate (ADC) research released at World ADC San Diego 2026. Results highlighted the pre-cli

Responsible AI for Children: IEEE Delivers a Trusted Safety Formula to Help Protect Kids Online14.10.2026 14:00:00 CEST | Press release

With children’s AI exposure surging, IEEE Standards Association certification helps ensure AI products for kids are ethically designed, independently tested and continually accountable for safety and well-beingFirst product certification issued to educational platform from Greek National Centre for Scientific Research The IEEE Standards Association, the global, consensus-building standards development organization of IEEE – the world’s largest technical professional organization and public charity dedicated to advancing technology for the benefit of humanity – today advanced its Responsible AI for Children (RAIC) Certification Program with the first product certified for children’s online safety. As children increasingly engage with digital and AI-enabled technologies, parents, educators, developers, and regulators want tools they can trust. IEEE’s Responsible AI for Children (RAIC) certification directly addresses these needs by translating global technical standards into a practical

Takeda Presents Phase 2/3 IgGNITE Study Results of Investigational Subcutaneous TAK-881 in Primary Immunodeficiency Disease (PID) at ESID 202614.10.2026 14:00:00 CEST | Press release

− TAK-881 met its primary endpoint, demonstrating pharmacokinetic comparability to HYQVIA® in patients 16 years and older − TAK-881 may shorten infusion times and offer the opportunity for fewer required infusion sites compared to HYQVIA with 50% less volume while maintaining up to once-monthly dosing − Adult infection outcomes and safety and tolerability profiles were comparable to HYQVIA based on descriptive analyses and consistent with established IG therapy standards Takeda (TSE:4502/NYSE:TAK) announced detailed results from the pivotal Phase 2/3 IgGNITE clinical trial (TAK-881-3001) evaluating investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) and Recombinant Human Hyaluronidase], which, if approved, has the potential to become the first facilitated SCIG 20% therapy for patients with Primary Immunodeficiency Disease (PID) administered up to once-monthly (every 3 to 4 weeks). Data in participants aged 16 years and older are featured in two late-b

Datavault AI Appoints Shareholder and Investment Executive Jeffrey Tirman to the Boardof Directors14.10.2026 13:55:00 CEST | Press release

Tirman, through his family office Abri Capital Ltd., holds 26 million DVLT shares and brings over 35 years of international investment management and corporate restructuring experience to the Company Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced the appointment of Jeffrey Tirman to its Board of Directors, effective as of October 12, 2026. Mr. Tirman was designated by NYIAX, Inc. (“NYIAX”) in connection with Datavault AI's recently completed acquisition of NYIAX, and he previously served on NYIAX's board of directors. As a Datavault AI Shareholder, Mr. Tirman brings both an ownership perspective and extensive management experience to the Board. Mr. Tirman has more than 35 years of international investment management experience, focused on corporate transformation, capital strategy and value creation. He has led c

EZO Reaches Financial Close on €150 Million Senior Debt Facility14.10.2026 13:21:00 CEST | Press release

Investment-grade, non-recourse financing will support the delivery of more than 3,000 charge points primarily across the whole of the UK along with additional development in Ireland. EZO has reached financial close on a €150 million investment-grade, non-recourse, senior debt facility. The funding will finance the design, installation, operation and maintenance of over 3,000 charge points, representing over 100,000 kWs of capacity, across the UK and Ireland under mostly long-term public sector “PPP-like” concessions with an attractive risk allocation between the public and private sector that will significantly advance EV infrastructure delivery, on time and to budget. These charge points are estimated to generate well in excess of £1 billion in electricity sales over the next 20 years, a portion of which will be shared with the public sector while, at the end of the concession, the chargers will revert back to the public sector. Headquartered in Ireland, EZO has expanded rapidly into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye